KR20120115390A - 삼중 음성 유방암의 치료요법에 대한 반응 예측 방법 - Google Patents

삼중 음성 유방암의 치료요법에 대한 반응 예측 방법 Download PDF

Info

Publication number
KR20120115390A
KR20120115390A KR1020127021091A KR20127021091A KR20120115390A KR 20120115390 A KR20120115390 A KR 20120115390A KR 1020127021091 A KR1020127021091 A KR 1020127021091A KR 20127021091 A KR20127021091 A KR 20127021091A KR 20120115390 A KR20120115390 A KR 20120115390A
Authority
KR
South Korea
Prior art keywords
expression
vegfr2
kit
her1
igf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127021091A
Other languages
English (en)
Korean (ko)
Inventor
신쥔 류
필립 김
리차드 커크랜드
타니 이
벨렌 이바론도
샤라트 싱
Original Assignee
네스텍 소시에테아노님
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 네스텍 소시에테아노님 filed Critical 네스텍 소시에테아노님
Publication of KR20120115390A publication Critical patent/KR20120115390A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
KR1020127021091A 2010-01-12 2011-01-12 삼중 음성 유방암의 치료요법에 대한 반응 예측 방법 Ceased KR20120115390A (ko)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US29443310P 2010-01-12 2010-01-12
US61/294,433 2010-01-12
US32562410P 2010-04-19 2010-04-19
US61/325,624 2010-04-19
US32860210P 2010-04-27 2010-04-27
US61/328,602 2010-04-27
US35183810P 2010-06-04 2010-06-04
US61/351,838 2010-06-04

Publications (1)

Publication Number Publication Date
KR20120115390A true KR20120115390A (ko) 2012-10-17

Family

ID=44304951

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127021091A Ceased KR20120115390A (ko) 2010-01-12 2011-01-12 삼중 음성 유방암의 치료요법에 대한 반응 예측 방법

Country Status (15)

Country Link
US (2) US9488654B2 (enExample)
EP (1) EP2524232B1 (enExample)
JP (1) JP5764144B2 (enExample)
KR (1) KR20120115390A (enExample)
CN (1) CN102822676B (enExample)
AU (1) AU2011205343B2 (enExample)
BR (1) BR112012017084A2 (enExample)
CA (1) CA2787225A1 (enExample)
ES (1) ES2505466T3 (enExample)
IL (1) IL220833A0 (enExample)
MX (1) MX2012008153A (enExample)
NZ (1) NZ601348A (enExample)
RU (1) RU2558931C2 (enExample)
WO (1) WO2011088149A2 (enExample)
ZA (1) ZA201206019B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101317809B1 (ko) 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
EP2788752B1 (en) * 2011-12-05 2018-10-03 Pierian Holdings, Inc. Method of therapy selection for patients with lung cancer
CA2862835A1 (en) * 2012-01-13 2013-07-18 Genentech, Inc. Biological markers for identifying patients for treatment with vegf antagonists
WO2014001232A1 (en) * 2012-06-26 2014-01-03 F. Hoffmann-La Roche Ag Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
US9422602B2 (en) 2012-08-15 2016-08-23 Bio-Rad Laboratories, Inc. Methods and compositions for determining nucleic acid degradation
WO2014071218A2 (en) * 2012-11-02 2014-05-08 University Of Utah Research Foundation Biomarkers for breast cancer and methods of using same
KR20140096571A (ko) 2013-01-28 2014-08-06 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
WO2015028974A2 (en) * 2013-08-30 2015-03-05 Nestec S.A. Polyp recurrence
ES2763429T5 (es) * 2013-12-17 2023-06-21 Hoffmann La Roche Procedimientos de tratamiento de cánceres usando antagonistas de la unión al eje de PD-1 y taxanos
EP3006940A1 (en) * 2014-10-10 2016-04-13 Ruprecht-Karls-Universität Heidelberg Biomarkers for predicting the response to anti-angiogenic cancer therapy
CN105891496A (zh) * 2014-12-09 2016-08-24 上海华盈生物医药科技有限公司 酪氨酸激酶抑制剂类靶向用药指导抗体芯片和检测方法
CN104830775B (zh) * 2015-04-14 2019-06-21 上海中医药大学附属龙华医院 一种三阴性乳腺癌顺铂耐药细胞株及其制备方法和用途
HRP20260689T1 (hr) 2015-06-17 2026-07-17 F. Hoffmann-La Roche Ag Postupci za liječenje lokalno uznapredovalog ili metastatskog raka dojke primjenom antagonista vezivanja osi pd-1 i taksana
US20180303830A1 (en) * 2015-06-22 2018-10-25 Thomas Jefferson University Cancers expressing ccr5 and methods of treatment of same
EP3363911B1 (en) * 2015-10-14 2024-09-25 Nitto Boseki Co., Ltd. Method for determining drug-sensitive human breast cancer cells by analysis method in which measurement of activity of two types of protein kinase is used
RU2616533C1 (ru) * 2016-03-15 2017-04-17 Федеральное государственное бюджетное научное учреждение "Томский научно-исследовательский институт онкологии" (Томский НИИ онкологии) Способ прогнозирования эффективности терапии эверолимусом у больных метастатическим раком почки
IL245861A0 (en) 2016-05-25 2016-09-04 Yeda Res & Dev Use of substances to treat drug-resistant tumors
CN109789204A (zh) * 2016-05-31 2019-05-21 雀巢产品技术援助有限公司 基于her2和her3通路亚型选择乳癌患者药物疗法的方法
CN106645728A (zh) * 2016-11-09 2017-05-10 百奥森（江苏）食品安全科技有限公司 一种食品中氟喹诺酮类药物的检测试剂盒
RU2648523C1 (ru) * 2017-05-22 2018-03-26 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр" Российской академии наук ("Томский НИМЦ") Способ прогнозирования исхода заболевания у больных люминальным в и трижды негативным раком молочной железы у пациенток, не получавших в неоадъювантном режиме химио- или гормонотерапию
CN109470854B (zh) * 2017-09-08 2022-02-11 广州市丹蓝生物科技有限公司 肺癌诊断用蛋白芯片及试剂盒
WO2019217942A1 (en) 2018-05-11 2019-11-14 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
US20210088523A1 (en) * 2019-09-23 2021-03-25 Sri International Methods for detecting circulating tumor cells in non-small cell lung cancer
US11366101B1 (en) 2020-12-31 2022-06-21 Elephas Biosciences Corporation Ex vivo systems and methods for determining the effect of a drug or other agent on a tissue
CN120731084A (zh) * 2023-03-15 2025-09-30 侯明宏 用于治疗三阴性乳癌的药物组合物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532138A (en) 1990-04-26 1996-07-02 Behringwerke Ag Method and kits for determining peroxidatively active catalysts
US5332662A (en) 1992-07-31 1994-07-26 Syntex (U.S.A.) Inc. Methods for determining peroxidatively active substances
WO1995006877A1 (en) 1993-09-03 1995-03-09 Behringwerke Ag Fluorescent oxygen channeling immunoassays
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US6897073B2 (en) 1998-07-14 2005-05-24 Zyomyx, Inc. Non-specific binding resistant protein arrays and methods for making the same
US6780582B1 (en) 1998-07-14 2004-08-24 Zyomyx, Inc. Arrays of protein-capture agents and methods of use thereof
US6197599B1 (en) 1998-07-30 2001-03-06 Guorong Chin Method to detect proteins
US7179638B2 (en) 1999-07-30 2007-02-20 Large Scale Biology Corporation Microarrays and their manufacture by slicing
CA2418105A1 (en) 2000-08-03 2002-02-14 Massachusetts Institute Of Technology Microarrays of functional biomolecules, and uses therefor
AU2002303384A1 (en) 2001-04-17 2002-10-28 William J. Dower Epitope-captured antibody display
US20030153013A1 (en) 2002-11-07 2003-08-14 Ruo-Pan Huang Antibody-based protein array system
US20060263837A1 (en) 2004-06-17 2006-11-23 Liu George D Immunoassay system and method for detection of antigens
CN103169729A (zh) * 2005-02-18 2013-06-26 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
US7771955B2 (en) 2005-06-09 2010-08-10 University Of Maryland Affinity membrane for capture of a target biomolecule and formation thereof by site-directed immobilization of a capture biomolecule
CN104198705B (zh) * 2006-09-21 2017-06-09 雀巢产品技术援助有限公司 检测稀有循环细胞内多种信号转导分子的基于抗体的阵列
RU2341198C2 (ru) * 2006-11-27 2008-12-20 ФГУ Ростовский научно-исследовательский онкологический институт Росздрава Способ оценки ангиогенных факторов при химиотерапии рака молочной железы
EP2109686A2 (en) * 2007-01-18 2009-10-21 University Of Southern California Genetic markers for predicting responsiveness to combination therapy
JP2010540459A (ja) * 2007-09-24 2010-12-24 トラガラ ファーマシューティカルズ，インク． Ｃｏｘ‐２阻害薬及びｅｇｆｒ［ｅｒｂｂ１］とｈｅｒ‐２［ｅｒｂｂ２］の二重阻害薬を用いた癌を治療するための併用療法
ES2553390T3 (es) * 2008-02-25 2015-12-09 Nestec S.A. Método para la detección de receptores truncados intracelulares
US8071315B2 (en) * 2008-04-30 2011-12-06 Sanford-Burnham Medical Research Institute Detecting Bcl-B expression in cancer and uses thereof
NZ596468A (en) 2009-05-14 2013-11-29 Nestec Sa Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
CA2804350A1 (en) * 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer

Also Published As

Publication number Publication date
AU2011205343A1 (en) 2012-08-02
US10697967B2 (en) 2020-06-30
US9488654B2 (en) 2016-11-08
JP5764144B2 (ja) 2015-08-12
ZA201206019B (en) 2015-06-24
WO2011088149A3 (en) 2011-10-27
CN102822676B (zh) 2015-02-18
RU2558931C2 (ru) 2015-08-10
AU2011205343B2 (en) 2015-08-13
MX2012008153A (es) 2012-11-06
BR112012017084A2 (pt) 2016-04-12
CN102822676A (zh) 2012-12-12
EP2524232A2 (en) 2012-11-21
EP2524232A4 (en) 2013-06-12
HK1178602A1 (en) 2013-09-13
US20130012407A1 (en) 2013-01-10
US20170227542A1 (en) 2017-08-10
WO2011088149A2 (en) 2011-07-21
IL220833A0 (en) 2012-08-30
CA2787225A1 (en) 2011-07-21
EP2524232B1 (en) 2014-08-06
JP2013517461A (ja) 2013-05-16
ES2505466T3 (es) 2014-10-10
RU2012134390A (ru) 2014-02-20
NZ601348A (en) 2014-07-25

Similar Documents

Publication Publication Date Title
US10697967B2 (en) Methods for predicting response of triple-negative breast cancer to therapy
JP5795311B2 (ja) 抗体ベースのアレイを使用する胃癌療法のための薬物選択
JP6186575B2 (ja) 治療有効性を判定するためのシグナル経路タンパク質のプロファイリング
CN103384828A (zh) 使用基于抗体的阵列进行恶性癌症疗法的药物选择
ES2639650T3 (es) Métodos para predecir y mejorar la supervivencia de pacientes con cáncer gástrico
JP6619339B2 (ja) ポリープ再発
HK1178602B (en) Methods for predicting response of triple-negative breast cancer to therapy

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000